Suppr超能文献

一种针对易长痤疮皮肤的局部噬菌体凝胶的研发及一项1期化妆品随机临床试验的结果。

Development of a topical bacteriophage gel targeting for acne prone skin and results of a phase 1 cosmetic randomized clinical trial.

作者信息

Golembo M, Puttagunta S, Rappo U, Weinstock E, Engelstein R, Gahali-Sass I, Moses A, Kario E, Ben-Dor Cohen E, Nicenboim J, Ben David H, Sudakov K, Cohen A, Bassan M, Zak N B

机构信息

BiomX Ltd Ness Ziona Israel.

BiomX Inc Branford Connecticut USA.

出版信息

Skin Health Dis. 2022 Jan 28;2(2):e93. doi: 10.1002/ski2.93. eCollection 2022 Jun.

Abstract

BACKGROUND

Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in , a bacterium implicated in acne pathophysiology. Bacteriophage (phage), which specifically target by a different mechanism of action and do not harm potentially beneficial bacteria, may offer an alternative approach for improvement of the appearance of acne prone skin.

OBJECTIVES

To identify and characterize targeting phage, carry out a comprehensive preclinical safety evaluation of phages selected for further development and examine their safety, tolerability and ability to target facial when applied topically in a cosmetic clinical study including participants with mild-to-moderate acne.

METHODS

Phages were isolated by conventional microbiological methods also used to examine their breadth of host range on different strains and specificity to this bacterial species. Safety assessment of three selected phages was carried out by complete genomic analysis to assure the absence of undesired sequences and by ex vivo models employed to evaluate the safety, irritability and potential systemic bioavailability of phage applied topically. A randomized, controlled clinical study assessed safety, tolerability and efficacy in targeting facial .

RESULTS

Wide host range phages that also target antibiotic resistant were identified. Their genomes were shown to be free of undesired genes. The three-phage cocktail, BX001, was not irritant to human skin or ocular tissues in ex vivo models and did not permeate through human epidermis. In a cosmetic clinical study, topically applied BX001 was safe and well tolerated and reduced the facial burden of .

CONCLUSIONS

Combined in silico and ex vivo approaches successfully predicted the observed safety and efficacy of targeting phage when these were topically administered in a well-controlled cosmetic clinical study.

摘要

背景

外用抗生素常用于治疗寻常痤疮。其长期使用,且使用时间常常超过推荐时长,已导致痤疮丙酸杆菌产生抗生素耐药性,该细菌与痤疮的病理生理学有关。噬菌体通过不同作用机制特异性靶向痤疮丙酸杆菌,且不会伤害潜在有益细菌,可能为改善易长痤疮皮肤的外观提供一种替代方法。

目的

鉴定并表征靶向痤疮丙酸杆菌的噬菌体,对选定用于进一步开发的噬菌体进行全面的临床前安全性评估,并在一项包括轻至中度痤疮参与者的美容临床研究中,检查其局部应用于面部痤疮丙酸杆菌时的安全性、耐受性和靶向能力。

方法

通过常规微生物学方法分离噬菌体,这些方法也用于检测其在不同痤疮丙酸杆菌菌株上的宿主范围广度以及对该细菌物种的特异性。通过全基因组分析对三种选定的噬菌体进行安全性评估,以确保不存在不良序列,并通过体外模型评估局部应用噬菌体的安全性、刺激性和潜在的全身生物利用度。一项随机对照临床研究评估了靶向面部痤疮丙酸杆菌的安全性、耐受性和疗效。

结果

鉴定出了也靶向抗生素耐药痤疮丙酸杆菌的广宿主范围噬菌体。其基因组显示不含不良基因。三噬菌体混合物BX001在体外模型中对人体皮肤或眼组织无刺激性,且不会渗透过人体表皮。在一项美容临床研究中,局部应用BX001是安全且耐受性良好的,并减轻了面部痤疮丙酸杆菌的负担。

结论

在一项严格控制的美容临床研究中,当局部施用靶向痤疮丙酸杆菌的噬菌体时,计算机模拟和体外方法相结合成功预测了观察到的安全性和疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c13/9168013/67fe76402dc0/SKI2-2-e93-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验